Viela Bio teams with Japanese pharma firm, gets $30M payment

Viela Bio Inc. is working with a Japanese pharmaceutical company to look at developing commercializing the Maryland firm's investigational new drug to treat a rare disease of the brain and spinal cord in Asia.

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *